{
  "symbol": "LLY",
  "year": 2023,
  "metrics": {
    "mdna_sentiment": -0.2732,
    "outlook_sentiment": 0.1751,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.181
  },
  "top_positive": [
    {
      "sent": "79 Fair Value of Risk-Management Instruments The following table summarizes certain fair value information at December\u00a031, 2022 and 2021 for risk-management assets and liabilities measured at fair value on a recurring basis: Fair Value Measurements Using Carrying Amount Quoted Prices in Active Markets for Identical Assets (Level\u00a01) Significant Other Observable Inputs (Level\u00a02) Significant Unobservable Inputs (Level 3) Fair Value December 31, 2022 Risk-management instruments Interest rate contracts designated as fair value hedges: Other noncurrent liabilities $ ( 134.3 ) \u2014 $ ( 134.3 ) \u2014 $ ( 134.3 ) Interest rate contracts designated as cash flow hedges: Other receivables 162.9 \u2014 162.9 \u2014 162.9 Other noncurrent assets 246.0 \u2014 246.0 \u2014 246.0 Cross-currency interest rate contracts designated as net investment hedges: Other receivables 67.6 \u2014 67.6 \u2014 67.6 Cross-currency interest rate contracts designated as cash flow hedges: Other noncurrent assets 53.1 \u2014 53.1 \u2014 53.1 Foreign exchange contracts designated as hedging instruments: Other current liabilities ( 38.3 ) \u2014 ( 38.3 ) \u2014 ( 38.3 ) Foreign exchange contracts not designated as hedging instruments: Other receivables 26.6 \u2014 26.6 \u2014 26.6 Other current liabilities ( 21.5 ) \u2014 ( 21.5 ) \u2014 ( 21.5 ) Contingent consideration liabilities: Other current liabilities ( 39.5 ) \u2014 \u2014 ( 39.5 ) ( 39.5 ) Other noncurrent liabilities ( 70.6 ) \u2014 \u2014 ( 70.6 ) ( 70.6 ) 80 Fair Value Measurements Using Carrying Amount Quoted Prices in Active Markets for Identical Assets (Level\u00a01) Significant Other Observable Inputs (Level\u00a02) Significant Unobservable Inputs (Level 3) Fair Value December 31, 2021 Risk-management instruments Interest rate contracts designated as fair value hedges: Other receivables $ 4.8 $ \u2014 $ 4.8 $ \u2014 $ 4.8 Other noncurrent assets 78.3 \u2014 78.3 \u2014 78.3 Other noncurrent liabilities ( 7.6 ) \u2014 ( 7.6 ) \u2014 ( 7.6 ) Interest rate contracts designated as cash flow hedges: Other noncurrent assets 49.2 \u2014 49.2 \u2014 49.2 Other noncurrent liabilities ( 31.7 ) \u2014 ( 31.7 ) \u2014 ( 31.7 ) Cross-currency interest rate contracts designated as net investment hedges: Other noncurrent assets 31.3 \u2014 31.3 \u2014 31.3 Other current liabilities ( 1.2 ) \u2014 ( 1.2 ) \u2014 ( 1.2 ) Cross-currency interest rate contracts designated as cash flow hedges: Other noncurrent assets 33.2 \u2014 33.2 \u2014 33.2 Other noncurrent liabilities ( 1.3 ) \u2014 ( 1.3 ) \u2014 ( 1.3 ) Foreign exchange contracts not designated as hedging instruments: Other receivables 9.9 \u2014 9.9 \u2014 9.9 Other current liabilities ( 35.3 ) \u2014 ( 35.3 ) \u2014 ( 35.3 ) Contingent consideration liabilities: Other noncurrent liabilities ( 70.5 ) \u2014 \u2014 ( 70.5 ) ( 70.5 ) Risk-management instruments above are disclosed on a gross basis.",
      "score": 0.9956
    },
    {
      "sent": "21 Our efforts in DEI and workplace benefits have garnered numerous recognitions, including, in 2022, Top 50 Companies for Diversity by DiversityInc., Top Companies for Board of Directors by DiversityInc., Top Companies for Supplier Diversity by DiversityInc., Top Companies for ESG by DiversityInc., America's Best Employers for Women by Forbes, Perfect Score on the Human Rights Campaign Foundation Corporate Equality Index, World's Most Ethical Companies by Ethisphere, Perfect Score on Disability Equity Index Best Places to Work by Disability:IN, Pharmaceutical Innovation Index, Zero Project Award for Access Lilly, and Top Companies for Executive Women, Best Companies for Multicultural Women, Best Companies for Dads, 70 percent and Higher Inclusion Index by Seramount.",
      "score": 0.992
    },
    {
      "sent": "21 Our efforts in DEI and workplace benefits have garnered numerous recognitions, including, in 2022, Top 50 Companies for Diversity by DiversityInc., Top Companies for Board of Directors by DiversityInc., Top Companies for Supplier Diversity by DiversityInc., Top Companies for ESG by DiversityInc., America's Best Employers for Women by Forbes, Perfect Score on the Human Rights Campaign Foundation Corporate Equality Index, World's Most Ethical Companies by Ethisphere, Perfect Score on Disability Equity Index Best Places to Work by Disability:IN, Pharmaceutical Innovation Index, Zero Project Award for Access Lilly, and Top Companies for Executive Women, Best Companies for Multicultural Women, Best Companies for Dads, 70 percent and Higher Inclusion Index by Seramount.",
      "score": 0.992
    }
  ],
  "top_negative": [
    {
      "sent": "The failure, inadequacy, or breach of our IT systems or business processes, the compromise, disruption, degradation, manipulation, loss, theft, destruction, or unauthorized access to, disclosure or use of, confidential information, or the unauthorized access to, disruption of, or interference with our products and services that rely on IT systems or business processes, could impair our ability to secure and maintain intellectual property rights; result in a product manufacturing interruption or failure, or in the interruption or failure of products or services that rely on IT systems or business processes; damage our operations, customer relationships, or reputation; undermine integration activities or otherwise delay the launch of acquired products; result in unfavorable clinical trial results by virtue of incorrect or unreliable data; and/or cause us to lose trade secrets or other competitive advantages.",
      "score": -0.981
    },
    {
      "sent": "The failure, inadequacy, or breach of our IT systems or business processes, the compromise, disruption, degradation, manipulation, loss, theft, destruction, or unauthorized access to, disclosure or use of, confidential information, or the unauthorized access to, disruption of, or interference with our products and services that rely on IT systems or business processes, could impair our ability to secure and maintain intellectual property rights; result in a product manufacturing interruption or failure, or in the interruption or failure of products or services that rely on IT systems or business processes; damage our operations, customer relationships, or reputation; undermine integration activities or otherwise delay the launch of acquired products; result in unfavorable clinical trial results by virtue of incorrect or unreliable data; and/or cause us to lose trade secrets or other competitive advantages.",
      "score": -0.981
    },
    {
      "sent": "The failure, inadequacy, or breach of our IT systems or business processes, the compromise, disruption, degradation, manipulation, loss, theft, destruction, or unauthorized access to, disclosure or use of, confidential information, or the unauthorized access to, disruption of, or interference with our products and services that rely on IT systems or business processes, could impair our ability to secure and maintain intellectual property rights; result in a product manufacturing interruption or failure, or in the interruption or failure of products or services that rely on IT systems or business processes; damage our operations, customer relationships, or reputation; undermine integration activities or otherwise delay the launch of acquired products; result in unfavorable clinical trial results by virtue of incorrect or unreliable data; and/or cause us to lose trade secrets or other competitive advantages.",
      "score": -0.981
    }
  ],
  "forward_snippets": [
    "The following include some but not all of the factors that could cause actual results or events to differ materially from those anticipated: \u2022 the significant costs and uncertainties in the pharmaceutical research and development process, including with respect to the timing and process of obtaining regulatory approvals; \u2022 the impact and outcome of acquisitions and business development transactions and related integration costs; \u2022 the expiration of intellectual property protection for certain of our products and competition from generic and/or biosimilar products; \u2022 our ability to protect and enforce patents and other intellectual property; \u2022 changes in patent law or regulations related to data package exclusivity; \u2022 competitive developments affecting current products and our pipeline; \u2022 market uptake of recently launched products; \u2022 information technology system inadequacies, breaches, or operating failures; \u2022 unauthorized access, disclosure, misappropriation, or compromise of confidential information or other data stored in our information technology systems, networks, and facilities, or those of third parties with whom we share our data; \u2022 the impact of global macroeconomic conditions, trade disruptions, disputes, unrest, war, regional dependencies, or other costs, uncertainties and risks related to engaging in business globally; \u2022 unexpected safety or efficacy concerns associated with our products; \u2022 litigation, investigations, or other similar proceedings involving past, current, or future products or commercial activities as we are largely self-insured; \u2022 issues with product supply and regulatory approvals stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, or regulatory actions related to our facilities; \u2022 dependence on certain products for a significant percentage of our total revenue and an increasingly consolidated supply chain; \u2022 reliance on third-party relationships and outsourcing arrangements; \u2022 the impact of public health outbreaks, epidemics, or pandemics, such as the COVID-19 pandemic; \u2022 regulatory changes or other developments; \u2022 regulatory actions regarding operations and products; \u2022 continued pricing pressures and the impact of actions of governmental and private payers affecting pricing of, reimbursement for, and access to pharmaceuticals; \u2022 devaluations in foreign currency exchange rates or changes in interest rates and inflation; \u2022 changes in tax law, tax rates, or events that differ from our assumptions related to tax positions; \u2022 asset impairments and restructuring charges; 3 \u2022 changes in accounting and reporting standards promulgated by the Financial Accounting Standards Board and the Securities and Exchange Commission (SEC); \u2022 regulatory compliance problems or government investigations; and \u2022 actual or perceived deviation from environmental-, social-, or governance-related requirements or expectations.",
    "The following include some but not all of the factors that could cause actual results or events to differ materially from those anticipated: \u2022 the significant costs and uncertainties in the pharmaceutical research and development process, including with respect to the timing and process of obtaining regulatory approvals; \u2022 the impact and outcome of acquisitions and business development transactions and related integration costs; \u2022 the expiration of intellectual property protection for certain of our products and competition from generic and/or biosimilar products; \u2022 our ability to protect and enforce patents and other intellectual property; \u2022 changes in patent law or regulations related to data package exclusivity; \u2022 competitive developments affecting current products and our pipeline; \u2022 market uptake of recently launched products; \u2022 information technology system inadequacies, breaches, or operating failures; \u2022 unauthorized access, disclosure, misappropriation, or compromise of confidential information or other data stored in our information technology systems, networks, and facilities, or those of third parties with whom we share our data; \u2022 the impact of global macroeconomic conditions, trade disruptions, disputes, unrest, war, regional dependencies, or other costs, uncertainties and risks related to engaging in business globally; \u2022 unexpected safety or efficacy concerns associated with our products; \u2022 litigation, investigations, or other similar proceedings involving past, current, or future products or commercial activities as we are largely self-insured; \u2022 issues with product supply and regulatory approvals stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, or regulatory actions related to our facilities; \u2022 dependence on certain products for a significant percentage of our total revenue and an increasingly consolidated supply chain; \u2022 reliance on third-party relationships and outsourcing arrangements; \u2022 the impact of public health outbreaks, epidemics, or pandemics, such as the COVID-19 pandemic; \u2022 regulatory changes or other developments; \u2022 regulatory actions regarding operations and products; \u2022 continued pricing pressures and the impact of actions of governmental and private payers affecting pricing of, reimbursement for, and access to pharmaceuticals; \u2022 devaluations in foreign currency exchange rates or changes in interest rates and inflation; \u2022 changes in tax law, tax rates, or events that differ from our assumptions related to tax positions; \u2022 asset impairments and restructuring charges; 3 \u2022 changes in accounting and reporting standards promulgated by the Financial Accounting Standards Board and the Securities and Exchange Commission (SEC); \u2022 regulatory compliance problems or government investigations; and \u2022 actual or perceived deviation from environmental-, social-, or governance-related requirements or expectations.",
    "We believe our long-term competitive success depends on discovering and developing (either alone or in collaboration with others) or acquiring innovative, cost-effective products that provide improved outcomes for patients and deliver value to payers, and continuously improving the productivity of our operations in a highly competitive environment.",
    "Biosimilars A number of our products and potential new medicines in our clinical-stage pipeline are biologics.",
    "Biosimilars A number of our products and potential new medicines in our clinical-stage pipeline are biologics."
  ]
}